Systemic lupus erythematosus (SLE) is a chronic, life threatening autoimmune disorder, leading to multiple organ pathologies and kidney destruction. Analyses of numerous murine models of spontaneous SLE have revealed a critical role for endosomal Toll-like receptors (TLRs) in the production of autoantibodies and development of other clinical disease manifestations. Nevertheless, the corresponding TLR9-deficient autoimmune-prone strains consistently develop more severe disease pathology. Injection of BALB/c mice with 2,6,10,14-tetramethylpentadecane (TMPD), commonly known as pristane, also results in the development of SLE-like disease. We now show that Tlr9−/− BALB/c mice injected intraperitoneally with TMPD develop more severe autoimmunity than their TLR-sufficient cohorts. Early indications include an increased accumulation of TLR7-expressing Ly6Chi inflammatory monocytes at the site of injection, upregulation of interferon regulated gene expression in the peritoneal cavity, and an increased production of myeloid lineage precursors (CMP and GMP) in the bone marrow. TMPD-injected Tlr9−/− BALB/c mice develop higher autoantibody titers against RNA, neutrophil cytoplasmic antigens (ANCA), and myeloperoxidase (MPO) than TMPD-injected WT BALB/c mice. The TMP-injected Tlr9−/− mice, and not the WT mice, also develop a marked increase in glomerular IgG deposition and infiltrating granulocytes, much more severe glomerulonephritis, and a reduced lifespan. Together the data point to a major role for TLR7 in the response to self-antigens in this model of experimental autoimmunity. Therefore the BALB/c pristane model recapitulates other TLR7-driven spontaneous models of SLE and is negatively regulated by TLR9.